Janus 1 - Phase 3 study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo with Capecitabine in Subjects with Adenocarcenoma of Pancreas intolerant to first-line chemotherapy
- Gurney, Howard (Primary Chief Investigator)
- Butala, Radhika, (Chief Investigator)
Project: Research